Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study von Cristofanilli, Massimo, Rugo, Hope S, Im, Seock-Ah, Slamon, Dennis J, Harbeck, Nadia, Bondarenko, Igor, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Iwata, Hiroji, O'Leary, Ben, André, Fabrice, Loibl, Sibylle, Bananis, Eustratios, Liu, Yuan, Huang, Xin, Kim, Sindy, Lechuga Frean, Maria Jose, Turner, Nicholas C

Volltext

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial von Loibl, Sibylle, Marmé, Frederik, Martin, Miguel, Untch, Michael, Bonnefoi, Hervé, Kim, Sung-Bae, Bear, Harry, McCarthy, Nicole, Melé Olivé, Mireia, Gelmon, Karen, García-Sáenz, José, Kelly, Catherine M, Reimer, Toralf, Toi, Masakazu, Rugo, Hope S, Denkert, Carsten, Gnant, Michael, Makris, Andreas, Koehler, Maria, Huang-Bartelett, Cynthia, Lechuga Frean, Maria Jose, Colleoni, Marco, Werutsky, Gustavo, Seiler, Sabine, Burchardi, Nicole, Nekljudova, Valentina, von Minckwitz, Gunter

Volltext

TREATMENT OF LUMINAL SUBTYPES OF HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER WITH PALBOCICLIB von LIU, Yuan, LECHUGA FREAN, Maria Jose, VALOTA, Olga, ZHANG, Zhe

Volltext bestellen